ProCE Banner Activity

Long-Acting CAB + RPV in Safety Net Clinic Population

Capsule Summary
Conference Coverage

In an adherence-challenged population with and without virologic suppression, virologic suppression rates were high and virologic failure rate was similar to the low rates in phase III trials of PWH with virologic suppression.

Released: February 23, 2023

Expiration: February 22, 2024

Begin Activity



Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare